Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2014; 20(15): 4244-4255
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4244
Table 1 Tumor nodes metastasis staging of rectal cancer based on the American Joint Committee on Cancer 7th edition
Primary tumor (T)
TxPrimary tumor cannot be assessed
T0No evidence of primary tumor
TisCarcinoma in situ
T1Tumor invades submucosa
T2Tumor invades muscularis propria
T3Tumor invades through the muscularis propria and into perirectal tissues
T4aTumor penetrates to the surface of the visceral peritoneum
T4bTumor directly invades or is adherent to other organs or structures
Regional lymph nodes (N)
NxRegional lymph nodes cannot be assessed
N0No regional lymph node metastasis
N1Metastases in 1-3 regional lymph nodes
N1aMetastasis in 1 regional lymph node
N1bMetastases in 2-3 regional lymph nodes
N1cTumor deposit(s) in the subserosa, mesentery, pericolic, or perirectal tissues without regional nodal metastasis
N2Metastases in 4 or more regional lymph nodes
N2aMetastases in 4-6 regional lymph nodes
N2bMetastases in 7 or more regional lymph nodes
Distant metastasis (M)
M0No distant metastasis
M1Distant metastasis
M1aMetastasis confined to 1 organ or site (e.g., liver, lung, ovary, non-regional node, external iliac lymph node)
M1bMetastases in > 1 organ/site or the peritoneum
Table 2 Advantages and disadvantages of imaging modalities in preoperative staging
Imaging modalitiesAdvantagesDisadvantages
Preoperative staging
EUSDepth of tumor invasion in early rectal cancerLimited field of view Perirectal invasion and LN metastasis
CTWide availability Fast scanning timeLocal staging and CRM involvement in lower rectal cancer
MRIHigh soft tissue resolution Local staging and CRM involvementDistant metastasis
PET/CTDistant metastasisPoor spatial resolution Perirectal invasion and CRM involvement
Post-therapeutic restaging
EUSNoneLow accuracy of T staging and LN staging
CTRelatively high accuracy of CRM statusRelatively low accuracy of T staging and LN staging
MRIHigh specificity of therapeutic response assessment High accuracy of CRM involvementRelatively poor sensitivity
PET/CTDistant metastasisNo standard parameter and follow-up protocol